BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022. Dr. Sauer will serve as a member of the Nomination and Corporate Governance Committee of the Board. He will also chair the Science and Innovation Committee, the purpose of which is to advise the Board on the company's research and development as well as clinical manufacturing and control strategies. Dr. Sauer succeeds Gerald Cagle, PhD, who is retiring from the Graybug Bo

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of Bettina Maunz as Chief People Officer. In addition to building and leading the human resources function for Graybug Vision, Ms. Maunz will serve as Head of Communications and be a member of the company’s executive team. “We are delighted for Bettina to join Graybug as Chief People Officer. Her leadership, culture and communications experience will be important assets to our team,” said Frederic Guera

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

4 - CalciMedica, Inc. (0001534133) (Issuer)

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) ("Graybug" or the "Company"), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the same period in 2021. Research and development expense for the quarter ended September 30, 2022 was $3.2 million compared to $4.0 million for the same period in 2021. The decrease was primarily due

BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Alternatives being explored include the potential for an acquisition, company sale, merger, d

Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter of 2023New programs for Retinitis Pigmentosa and Geographic AtrophyCurrent cash expected to fund planned operations into fourth quarter of 2023Graybug to host virtual Investor R&D Day today, March 30, 2022, beginning at 11 a.m. ET BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today an

Phase 2/3 ReMEDy2 Trial in AIS for Stroke Outcomes and Stroke Recurrence on Track for Initiation Summer 2021 Positive REDUX Phase 2 Interim Data Announced for CKD: IgA Nephropathy Data Indicate Statistically & Clinically Significant 33% Reduction in Albuminuria (UACR). Board of Directors Strengthened with Election of Two Pharma Industry Veterans  Conference Call and Webcast August 12 at 8:00 am Eastern Time / 7:00 am Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended June 3

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and six months ended June 30, 2021. Recent Corporate Developments Completed six-month extended observation period of ALTISSIMO Phase 2b trial in wet AMD— 28 of the 50 patients who completed their Month 12 visit were eligible and agreed to continue masked clinical monitoring until the point at which they required additional supportive therapy, up t

SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)

SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)

SC 13G - CalciMedica, Inc. (0001534133) (Subject)

SC 13G - CalciMedica, Inc. (0001534133) (Subject)

SC 13G - CalciMedica, Inc. (0001534133) (Subject)

SC 13G - CalciMedica, Inc. (0001534133) (Subject)

SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)

SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)

SVB Leerink downgraded Graybug Vision from Outperform to Market Perform and set a new price target of $5.00 from $23.00 previously

Needham downgraded Graybug Vision from Buy to Hold

SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously

Piper Sandler resumed coverage of Graybug Vision with a rating of Neutral and set a new price target of $10.00 from $27.00 previously

Wedbush resumed coverage of Graybug Vision with a rating of Neutral and set a new price target of $8.00 from $41.00 previously

Wedbush downgraded Graybug Vision from Outperform to Neutral and set a new price target of $8.00 from $41.00 previously

Wedbush downgraded Graybug Vision from Outperform to Neutral

SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously

Piper Sandler downgraded Graybug Vision from Overweight to Neutral and set a new price target of $10.00 from $27.00 previously

  On Monday, 198 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Equity Residential (NYSE:EQR) was the biggest company by market cap to set a new 52-week low. The smallest company by market cap to hit a new 52-week low was CNS Pharmaceuticals (NASDAQ:CNSP). Graybug Vision (NASDAQ:GRAY) shares traded down 1205.63% to reach its 52-week low, making it the biggest loser. VBI Vaccines (NASDAQ:VBIV)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. Stocks that set new 52-week lows on Monday are as follows: Equity Residential (NYSE:EQR) stock dropped to a yearly low on Monday of $57.10. Shares traded up 0.64%. CF Ind

Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to "CALC." The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica).

  On Wednesday, 152 stocks made new 52-week lows. Areas of Interest About Today's 52-Week Lows: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a new 52-week low. Pingtan Marine Enterprise (NASDAQ:PME) was the smallest company in terms of market cap to set a new 52-week low. Pingtan Marine Enterprise (NASDAQ:PME) shares traded down 99.97% to reach its 52-week low, making it the biggest loser. SmartRent (NYSE:SMRT) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. The following stocks created new 52-week lows on Wednesday: Tesla (NASDAQ:TSLA) shares moved up 1.51% on Wednesday to hit a new 52-week low of $135.89, dr

  On Friday, 127 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Lucid Gr (NASDAQ:LCID) was the largest company by market cap to set a new 52-week low. G Medical Innovations (NASDAQ:GMVD) is the smallest company on a market cap basis to set a new 52-week low. Autolus Therapeutics (NASDAQ:AUTL)'s stock fell the most, as it traded down 35.79% to reach a new 52-week low. Radiant Logistics (AMEX:RLGT) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. During the trading on Friday, the following stocks set new 52-week lows: Lucid Gr (NASDAQ:LCID) shares fell to $8.14 on Friday, setting a new 52-week low with a shift

  During Thursday's trading, 138 companies set new 52-week lows. Significant Points From Today's 52-Week Lows: Salesforce (NYSE:CRM) is the largest company in terms of market cap to set a new 52-week low this morning. Quotient (NASDAQ:QTNT) is the smallest company on a market cap basis to set a new 52-week low. Eiger BioPharmaceuticals (NASDAQ:EIGR)'s stock fell the most, as it traded down 71.95% to reach a new 52-week low. CareMax (NASDAQ:CMAX) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. Stocks dropping to new 52-week lows on Thursday: Salesforce (NYSE:CRM) shares reached a new 52-week low of $127.03 on

Gainers Cosmos Holdings Inc. (NASDAQ:COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda. Palisade Bio, Inc. (NASDAQ:PALI) shares climbed 81.1% to close at $4.02 on Tuesday after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery. Motorsport Games Inc. (NASDAQ:MSGM) gained 51.1% to settle at $6.80. The company recently posted downbeat quarterly results. FOXO Technologies Inc. (NYSE:FOXO) surged 47.6% to close at $0.72. Foxo Technologies, sai

Gainers Palisade Bio (NASDAQ:PALI) shares moved upwards by 127.8% to $5.04 during Tuesday's regular session. As of 12:30 EST, Palisade Bio's stock is trading at a volume of 44.9 million, which is 28949.4% of its average full-day volume over the last 100 days. The company's market cap stands at $7.1 million. Cosmos Holdings (NASDAQ:COSM) shares moved upwards by 46.17% to $0.26. As of 12:30 EST, Cosmos Holdings's stock is trading at a volume of 222.4 million, which is 1495.2% of its average full-day volume over the last 100 days. The company's market cap stands at $21.4 million. Cingulate (NASDAQ:CING) shares moved upwards by 32.21% to $0.91. The current volume of 357.0K shares is 490.3% of

  During Tuesday's trading, 160 companies set new 52-week lows. 52-Week Low Highlights: Tesla (NASDAQ:TSLA) is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company by market cap to set a new 52-week low was Baudax Bio (NASDAQ:BXRX). Ebang Intl Hldgs (NASDAQ:EBON)'s stock dropped the most, trading down 2541.34% to reach a new 52-week low. NightHawk Biosciences (AMEX:NHWK) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. Stocks that set new 52-week lows on Tuesday are as follows: Tesla (NASDAQ:TSLA) stock dropped to a yearly low on Tuesday of $166.19. Shares trad

Graybug Vision Inc (NASDAQ:GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction.  The combined company will further develop CalciMedica's lead product candidate Auxora for inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results and a favorable safety profile. With approximately $35 million in cash and cash equiva

Gainers OncoSec Medical (NASDAQ:ONCS) shares rose 31.9% to $6.4 during Tuesday's pre-market session. The market value of their outstanding shares is at $11.4 million. TransCode Therapeutics (NASDAQ:RNAZ) shares rose 20.61% to $0.58. The market value of their outstanding shares is at $7.5 million. BrainsWay (NASDAQ:BWAY) shares moved upwards by 17.8% to $2.25. The company's market cap stands at $37.1 million. As per the news, the Q3 earnings report came out 4 days ago. Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 16.02% to $0.65. The company's market cap stands at $28.2 million. Accelerate Diagnostics (NASDAQ:AXDX) stock increased by 13.03% to $1.04. The market value of t